Investigational drug · Phase 2
VH4011499
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for HIV Infections.
Phase 2Last checked: Nov 20, 2026Latest source record: Sep 11, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
8
Any phase or sponsor naming "VH4011499"
First trial start
2026
Oct 19, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "VH4011499", any sponsor or status.
Conditions studied
As listed on its trial records.
- HIV Infections
Approved drugs for the same conditions: Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "VH4011499" as an intervention, largest first.
- A Phase 2b Study Evaluating VH4011499 Capsid Inhibitor Long-Acting Injectable Plus Cabotegravir in Treatment Naïve Adults (CINERGY)Pivotal-lookingNot yet recruiting
ViiV HealthcareGSK (GSK)
NCT07816250 · 200 participants (planned) · Start Oct 19, 2026 · Primary completion Jun 10, 2032
Drug: VH4011499; CAB and 1 more · For: HIV Infections
- A Study to Assess the Safety, Tolerability, and Pharmacokinetics of VH4011499 Compared to Placebo in Adults Without HIVPivotal-lookingRecruiting
ViiV HealthcareGSK (GSK)
NCT06724640 · 168 participants (planned) · Start Dec 16, 2024 · Primary completion Aug 16, 2028
Drug: VH4011499 low dose Injection; VH4011499 high dose Injection and 1 more · For: HIV Infections
Sites: Las Vegas, Nevada; Austin, Texas
ViiV HealthcareGSK (GSK)
NCT06012136 · 85 participants · Start Aug 24, 2023 · Primary completion Jun 9, 2026
Drug: VH4004280; Placebo and 1 more · For: HIV Infections
Sites: Las Vegas, Nevada; Austin, Texas
- An Evaluation of the Potential for VH4011499 Drug-drug-interactionsNot yet recruiting
ViiV HealthcareGSK (GSK)
NCT07939594 · 75 participants (planned) · Start Nov 16, 2026 · Primary completion Mar 12, 2027
Drug: VH4011499; Ritonavir and 6 more · For: HIV Infections
ViiV HealthcareGSK (GSK)
NCT05393271 · 73 participants · Start Oct 3, 2022 · Primary completion Apr 24, 2023
Drug: VH4011499; Placebo and 1 more · For: HIV Infections
Sites: Las Vegas, Nevada; Austin, Texas
ViiV HealthcareGSK (GSK)
NCT06368986 · 60 participants · Start Apr 17, 2024 · Primary completion Oct 2, 2024
Drug: VH4011499 Dose A; VH4011499 Dose B · For: HIV Infections
Sites: Austin, Texas
ViiV HealthcareGSK (GSK)
NCT06039579 · 44 participants · Start Oct 25, 2023 · Primary completion Jun 24, 2024
Drug: VH4004280; VH4011499 and 3 more · For: HIV Infections
Sites: Bakersfield, California; DeLand, Florida; Newark, New Jersey · 20 sites in all
- Mass Balance and Absolute Bioavailability of [14C]-VH4011499Not yet recruiting
ViiV HealthcareGSK (GSK)
NCT07934719 · 18 participants (planned) · Start Nov 9, 2026 · Primary completion Feb 18, 2027
Drug: VH4011499; [14C]-VH4011499 (IV) and 1 more · For: HIV Infections
Newest research
PubMed records naming it or its code names, newest first.
- Antiviral Effect, Safety, and Tolerability of Oral VH4011499 (VH-499), a New HIV-1 Capsid Inhibitor: Proof-of-Concept Trial.
Griesel R, Nuñez SA, Cordova E, et al. · Clin Infect Dis 2026
- Preclinical virology profiles of the HIV-1 capsid inhibitors VH4004280 and VH4011499.
Wang C, Huang H, Valera L, et al. · Antimicrob Agents Chemother 2025
- Clinical Pharmacokinetics and Safety of Orally Administered VH4011499, a New HIV-1 Capsid Inhibitor, in Adults Without HIV.
Thakkar N, Griesel R, Pierce A, et al. · Infect Dis Ther 2025
- Current status of the small molecule anti-HIV drugs in the pipeline or recently approved.
Umumararungu T, Nyandwi JB, Katandula J, et al. · Bioorg Med Chem 2024
Also in development for HIV Infections
- rHuPH20Phase 35 trials
Bristol Myers Squibb · Melanoma, Relapsing-remitting Multiple Sclerosis, Clear Cell Renal Cell Carcinoma
- TeropavimabTAB, GS-5423Phase 33 trials
Gilead Sciences · HIV-1 Infection, HIV Infections, HIV-1-infection
- ZinlirvimabGS-2872, ZABPhase 33 trials
Gilead Sciences · HIV-1 Infection, HIV Infections, HIV-1-infection
- 2 NRTIsPhase 32 trials
Merck & Co. · Human Immunodeficiency Virus (HIV) Infection, Infection, Human Immunodeficiency Virus, HIV Infections
- ABC3TC STR, 3TC immediate releasePhase 32 trials
GSK · HIV Infections
- ARTPhase 32 trials
GSK · HIV Infections, HIV-1 Infection
- DTGPhase 32 trials
Jiangsu Aidea Pharmaceutical Group Co., Ltd. · Infection, Human Immunodeficiency Virus, HIV Infections
- BMS-663068Phase 31 trial
GSK · HIV Infections
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from GSK.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.